Publications by authors named "A Belotti"

The use of minimalist shoes can lead to enhanced foot somatosensory activation and postural stability but can also increase the incidence of overuse injuries during high-impact or prolonged activities. Therefore, it appears useful to explore new strategies that employ minimalist shoes to effectively facilitate the somatosensory activation of the foot while minimizing acute and cumulative joint stress and risk of injury. To this purpose, this study introduces a novel exercise paradigm: walking for three minutes in ultra-minimalist shoes on artificial flat surfaces designed to mimic highly rugged natural terrains.

View Article and Find Full Text PDF
Article Synopsis
  • - The PERSEUS study analyzed the effects of adding daratumumab (D) to the standard treatment VRd (bortezomib, lenalidomide, and dexamethasone) for adults with newly diagnosed multiple myeloma to see if it could improve outcomes.
  • - Participants were divided into two groups: one receiving D-VRd initially followed by D-R maintenance, and the other receiving standard VRd followed by lenalidomide alone.
  • - After about four years, results indicated that those who received D-VRd had better treatment responses and were more likely to remain alive and disease-free compared to the VRd-only group, with side effects being consistent with expectations for both treatments.
View Article and Find Full Text PDF

Protonic ceramic fuel cells (PCFCs) offer a promising, clean, and efficient energy conversion solution. However, thermal mismatch between cathodes and electrolytes remains a critical obstacle, leading to interfacial damage such as cracking and delamination. Incorporating negative thermal expansion (NTE) materials into the cathode can mitigate this issue.

View Article and Find Full Text PDF

Belantamab mafodotin is the first-in-class antibody-drug conjugates targeting B-cell maturation antigen to have demonstrated effectiveness in triple-class refractory multiple myeloma (TCR-MM) patients. We performed a retrospective study including 78 TCR patients, with at least four prior lines of therapy (LOTs), who received belantamab mafodotin within named patient program and expanded access program in Italy between 2020 and 2022. Median age was 65 years (range 42-86 years), ECOG performance status was ≥1 in 45% of patients.

View Article and Find Full Text PDF

Additional copies of chromosome 1 long arm (1q) are frequently found in multiple myeloma (MM) and predict high-risk disease. Available data suggest a different outcome and biology of patients with amplification (Amp1q, ≥4 copies of 1q) vs. gain (Gain1q, 3 copies of 1q) of 1q.

View Article and Find Full Text PDF